Nevirapin Aurobindo (Nevirapine)

Nevirapine, the active ingredient in Nevirapin Aurobindo, is a Non-nucleoside reverse transcriptase inhibitor (NNRTI) presented as an oral tablet for oral use. It treats HIV-1 infection in adults and children as part of combination antiretroviral therapy.

GNH USA supplies Nevirapin Aurobindo as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Clients benefit from consistent product availability and regulatory support across EU and other markets.

Nevirapine is an NNRTI used in antiretroviral regimens to control HIV-1 replication.

- HIV-1 infection (adults): reduces plasma viral load and improves CD4+ cell counts when combined with other antiretrovirals. - HIV-1 infection (children ≥2 years): contributes to virologic suppression as part of pediatric combination therapy.

Nevirapine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Rash: mild to moderate skin eruptions. - Nausea: occasional upset stomach. - Fatigue: generalized tiredness. - Headache: mild to moderate intensity. - Dizziness: transient light‑headedness. - Abdominal pain: discomfort in the stomach area.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention. - Toxic epidermal necrolysis: life‑threatening skin detachment. - Severe hepatic failure: marked liver enzyme elevation or liver injury. - Hypersensitivity reactions: including fever, eosinophilia, and organ involvement. - Grade 3/4 neutropenia: significant reduction in neutrophil count. - Severe anemia: marked drop in hemoglobin levels.

When prescribing nevirapine, clinicians should observe several safety considerations to minimize risk.

- Monitor liver function: assess transaminases before initiation and periodically during therapy. - Avoid use in patients with known hypersensitivity to nevirapine or related compounds. - Do not start therapy in pregnant women beyond the first trimester without specialist advice. - Assess CD4 count before initiation, especially in women, to reduce risk of severe rash. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Nevirapine interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Ritonavir‑boosted protease inhibitors: may increase nevirapine levels, raising toxicity risk. - Efavirenz: concurrent use can lower nevirapine concentrations, reducing efficacy. - St. John's wort: induces metabolism, leading to decreased nevirapine exposure.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., ketoconazole): may raise nevirapine levels. - Macrolide antibiotics (e.g., erythromycin): can affect plasma concentrations. - Oral contraceptives: nevirapine may reduce hormonal effectiveness; consider alternative contraception.